Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

App aims to improve life for brain tumor patients

NCT ID NCT07439302

First seen Mar 02, 2026 · Last updated Jun 20, 2026 · Updated 16 times

Summary

This study will test whether a mobile app called Resilience PRO can help monitor symptoms and quality of life in 80 adults with IDH-mutated glioma who are starting a new systemic treatment. Participants will use the app to report side effects and complete questionnaires every two weeks. The goal is to see if remote monitoring can catch problems early and improve care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Service de Neuro-oncologie, Hôpital de la Pitié-Salpêtrière

    Paris, 75013, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Resilience PRO mobile app for symptom monitoring

What this could lead to

If successful, this could show that remote symptom tracking improves quality of life and reduces hospital visits for people with this type of brain tumor.

What could go wrong

This is an observational study, not a treatment trial. It may not prove that the app directly improves outcomes, and results may vary across different patients.

Conditions

The condition(s) this trial relates to.

glioma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.